A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial

Claudio Bilardi, Pietro Dulbecco, Patrizia Zentilin, Simona Reglioni, Elena Iiritano, Andrea Parodi, Laura Accornero, Edoardo Savarino, Carlo Mansi, Mario Mamone, Sergio Vigneri, Vincenzo Savarino

Research output: Contribution to journalArticle

Abstract

Background & Aims: Antibiotic resistance is a major issue in anti-Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily for the first week and omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week. Therapeutic success was evaluated by 13C urea breath test after 4 weeks of treatment. Results: We enrolled 44 patients in the levofloxacin-based regimen and 46 patients in the quadruple therapy. The former was successful in 31 of 44 (70%; 95% confidence interval: 53-87) and the latter in 17 of 46 (37%; 95% confidence interval: 23-47) patients, using intention-to-treat (ITT) analysis (P

Original languageEnglish
Pages (from-to)997-1002
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume2
Issue number11
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Levofloxacin
Helicobacter Infections
Helicobacter pylori
Omeprazole
Amoxicillin
Metronidazole
Therapeutics
Confidence Intervals
Intention to Treat Analysis
Breath Tests
Gastrointestinal Endoscopy
Clarithromycin
Pylorus
Microbial Drug Resistance
Group Psychotherapy
Tetracycline
Urea
Histology
Biopsy
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection : A controlled trial. / Bilardi, Claudio; Dulbecco, Pietro; Zentilin, Patrizia; Reglioni, Simona; Iiritano, Elena; Parodi, Andrea; Accornero, Laura; Savarino, Edoardo; Mansi, Carlo; Mamone, Mario; Vigneri, Sergio; Savarino, Vincenzo.

In: Clinical Gastroenterology and Hepatology, Vol. 2, No. 11, 11.2004, p. 997-1002.

Research output: Contribution to journalArticle

Bilardi, C, Dulbecco, P, Zentilin, P, Reglioni, S, Iiritano, E, Parodi, A, Accornero, L, Savarino, E, Mansi, C, Mamone, M, Vigneri, S & Savarino, V 2004, 'A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial', Clinical Gastroenterology and Hepatology, vol. 2, no. 11, pp. 997-1002. https://doi.org/10.1016/S1542-3565(04)00458-6
Bilardi, Claudio ; Dulbecco, Pietro ; Zentilin, Patrizia ; Reglioni, Simona ; Iiritano, Elena ; Parodi, Andrea ; Accornero, Laura ; Savarino, Edoardo ; Mansi, Carlo ; Mamone, Mario ; Vigneri, Sergio ; Savarino, Vincenzo. / A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection : A controlled trial. In: Clinical Gastroenterology and Hepatology. 2004 ; Vol. 2, No. 11. pp. 997-1002.
@article{59dbb12c4c49463a8bf409eb88b122b1,
title = "A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial",
abstract = "Background & Aims: Antibiotic resistance is a major issue in anti-Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily for the first week and omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week. Therapeutic success was evaluated by 13C urea breath test after 4 weeks of treatment. Results: We enrolled 44 patients in the levofloxacin-based regimen and 46 patients in the quadruple therapy. The former was successful in 31 of 44 (70{\%}; 95{\%} confidence interval: 53-87) and the latter in 17 of 46 (37{\%}; 95{\%} confidence interval: 23-47) patients, using intention-to-treat (ITT) analysis (P",
author = "Claudio Bilardi and Pietro Dulbecco and Patrizia Zentilin and Simona Reglioni and Elena Iiritano and Andrea Parodi and Laura Accornero and Edoardo Savarino and Carlo Mansi and Mario Mamone and Sergio Vigneri and Vincenzo Savarino",
year = "2004",
month = "11",
doi = "10.1016/S1542-3565(04)00458-6",
language = "English",
volume = "2",
pages = "997--1002",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection

T2 - A controlled trial

AU - Bilardi, Claudio

AU - Dulbecco, Pietro

AU - Zentilin, Patrizia

AU - Reglioni, Simona

AU - Iiritano, Elena

AU - Parodi, Andrea

AU - Accornero, Laura

AU - Savarino, Edoardo

AU - Mansi, Carlo

AU - Mamone, Mario

AU - Vigneri, Sergio

AU - Savarino, Vincenzo

PY - 2004/11

Y1 - 2004/11

N2 - Background & Aims: Antibiotic resistance is a major issue in anti-Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily for the first week and omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week. Therapeutic success was evaluated by 13C urea breath test after 4 weeks of treatment. Results: We enrolled 44 patients in the levofloxacin-based regimen and 46 patients in the quadruple therapy. The former was successful in 31 of 44 (70%; 95% confidence interval: 53-87) and the latter in 17 of 46 (37%; 95% confidence interval: 23-47) patients, using intention-to-treat (ITT) analysis (P

AB - Background & Aims: Antibiotic resistance is a major issue in anti-Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily for the first week and omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week. Therapeutic success was evaluated by 13C urea breath test after 4 weeks of treatment. Results: We enrolled 44 patients in the levofloxacin-based regimen and 46 patients in the quadruple therapy. The former was successful in 31 of 44 (70%; 95% confidence interval: 53-87) and the latter in 17 of 46 (37%; 95% confidence interval: 23-47) patients, using intention-to-treat (ITT) analysis (P

UR - http://www.scopus.com/inward/record.url?scp=9144258031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144258031&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(04)00458-6

DO - 10.1016/S1542-3565(04)00458-6

M3 - Article

C2 - 15551252

AN - SCOPUS:9144258031

VL - 2

SP - 997

EP - 1002

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 11

ER -